U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07384429) titled 'Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease' on Jan. 26.
Brief Summary: The aim of this study is to explore the effects of the dual orexin receptor antagonist Lemborexant on improving motor and sleep comorbidity in patients with Parkinson's disease. This study will provide clinical evidence for the application of dual orexin receptor antagonists in the treatment of Parkinson's Disease.
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Parkinson's Disease
Insomnia
Motor Disorder
Intervention:
DRUG: Lemborexant
Participants will receive oral Lemborexant (5 mg/day) nightly approximately ...